In cancer research, transcriptional aberrations are often deduced from mRNA-based gene expression profiling (GEP). Although transcriptome sequencing (RNA-seq) has gained ground in the recent past, mRNA-based microarrays remain a useful asset for high-throughput experiments in many laboratories. Possible reasons are the lower per-sample costs and the opportunity to analyze obtained GEP data in association with published data sets. There are established and widely used methods for the analysis of microarray data, which increase the comparability of different GEP data sets and facilitate data-mining approaches. However, analytic pitfalls, such as batch effects and issues of sample purity, e.g. by complex tissue composition, are often not properly addressed by these standard approaches. Moreover, most of these tools do not capitalize on the full range of public data sources or do not take advantage of the analytic possibilities for functional interpretation or of comprehensive meta-analyses. We present an overview of the most critical steps in the analysis of microarray-based GEP data. We discuss software and database query solutions that may be useful for
Introduction
Traditionally, gene expression analysis includes reverse transcription of mRNA into cDNA and probing of gene transcripts of interest by specific primers designed for target PCR amplification (gold standard), followed by quantitative, semi-quantitative (e.g. qRT-PCR), or electrophoresis (e.g. Southern blotting) detection methods. Based on efforts provided by the Human Genome Project [1, 2] and studies on expressed sequence tags (ESTs) in mammalian genomes, cDNA hybridization array chips have originally been designed to investigate deregulated mRNA expression of distinct and well-characterized gene transcripts in various diseases. Modern mRNA-microarray platforms apply one or two-color fluorescence labeling (i.e. Cyanine3 / Cy3 for green and Cy5 for red dye fluorescence) for one or two samples to be loaded on the chip, respectively, and allow the detection of more than 47 000 transcripts. In contrast to two-color arrays (e.g. HuA1 by Agilent Technologies, Santa Clara, CA, USA), one-color arrays, are most commonly used today (e.g. HG-U133 Plus 2.0 by Affymetrix, Inc., Santa Clara, CA, USA, or BeadArray HT-12v4, Illumina, Inc., San Diego, CA, USA) and represent the focus of this review.
The past few years have seen the advent of transcriptome sequencing (RNA-seq) based on the next-generation sequencing (NGS) technology using high-throughput platforms, such as the GA IIx or HiSeq2000 sequencer from Illumina. RNA-seq does not require the prior design of specific probes, rendering it a highly versatile approach for gene expression profiling (GEP). Accordingly, a number of publications on the genomic landscape of various neoplasms have applied RNA-seq to investigate gene-specific aspects such as differential splicing and exon usage [3] , hidden viral transcripts [4] , and cancer-specific fusion transcripts [5] . However, published reports using RNA-seq in cancer often lack statistical power for comprehensive gene expression analyses due to a limited sample size. In contrast, mRNA-based microarrays have remained the initial method of choice for high-throughput analyses of gene expression in many laboratories. Reasons for this include the associated lower per-sample costs as well as the availability of already published microarray-derived GEP data in 250 
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public databases. Many of these data sets were processed by established and widely used methods, thereby improving their comparability and the suitability for data-mining approaches.
Within this review, we present an overview of critical steps in the analysis of microarray-based GEP data (see overview in Figure 1 ) and the corresponding library and code information (summarized in Table 1 and 2). We will discuss step-by-step software and database query solutions that may be useful for data analysis, to avoid analytic pitfalls, and to provide an increased capability for clinical and biological interpretation of data. To illustrate the proposed analytic steps, we present analyses on exemplary data of previously published and own GEP data, all obtained in patients with B-and T-cell leukemias or lymphomas.
Quality Control can Greatly Differ by Platform
There are various possibilities to apply basic steps of quality control (QC) prior to or during preprocessing of GEP raw data. In order to avoid false estimates of background intensities and false inputs for normalization, removal of potential problematic samples and probes before data preprocessing is essential towards a correct interpretation of data. Problematic samples often present as outliers in density distributions or in an unsupervised cluster analysis on global gene expression values (after data preprocessing). The latter, e.g. in form of dendrograms (Code 1) or principal component analyses (PCA; Code 2), is created by using the R [7] library arrayQualityMetrics from
Bioconductor [8] with its informative HTML report per array.
Numerous methods and libraries for R are available for more specific quality assessments for each of the three major microarray platforms. Affymetrix arrays can be analyzed using the affyQCReport and simpleaffy libraries (see Table 1 for all library references), which normalize expression values using housekeeping genes (e.g. calculating the actin3/actin5 ratio), while the affyPLM library allows calculation of important quality measures such as the normalized unscaled standard error (NUSE) and relative log expression (RLE) as well as their plotting across samples 
Proper Preprocessing of Raw Data
A first step in the standard analysis protocol of cDNA microarrays usually is the conversion of hybridization image spots obtained by array scanners into raw gene expression values. For Affymetrix chips this is normally done either by using the freeware Affymetrix Power Tools or the R library affy. For Illumina's BeadChips the proprietary GenomeStudio software or manual decryption via the R library beadArray may be used. For two-color arrays, scanner output files, e.g. in TIF
format, can easily be read with the read.maimages function from the limma R library.
In a second step, background correction is conducted by subtracting technical noise from biological variation. This is accomplished by using e.g. RMA [9] for Affymetrix arrays or the bgAdjust function from the lumi R library for Illumina arrays, which employs a similar algorithm as GenomeStudio (Code 5). In order to account for outliers and to remove systematic variation, normalization of expression values is required. The most common procedures include quantile-normalization, which preserves the rank, but may eliminate small differences in expression values, and LOESS (locally weighted scatterplot smoothing)-normalization, which does the opposite.
Robust splice normalization (RSN) aims to combine the advantages of both methods through a 
Probe Annotation and Deconvolution
Frequent impediments for GEP data analysis are missing array annotations or outdated annotation files provided by the manufacturers (e.g. frequently old GenBank predictions are included). Data-mining tools such as biomaRt [12] can be used to acquire up-to-date probe information (Code 7). They may also be helpful in assigning probes to transcripts, thereby enabling filtering for redundancies of probes, which map primarily to transcripts that are prone to nonsense-mediated mRNA decay (NMD) or to unprocessed pseudogenes. Deconvolution of genes with known transcript variants of differential function into probed isoforms may also be important for extrapolations on biological relevance. An example is the apoptosis regulator myeloid cell leukemia sequence 1 (MCL1), of which the longer isoform (MCL1-001) has been reported to enhance survival by inhibiting apoptosis, while its shorter isoform (MCL1-002) acts as a pro-apoptotic molecule [13] .
Exploring Differentially Expressed Genes Considering the "Multiple Comparisons

Problem"
Raw data preprocessing and QC is followed by the actual statistical analysis, usually in the form of probe-by-probe hypothesis tests for differential expression including: (1) two-group mean comparisons using a Student's t-test (parametric, i.e. presuming a known statistical distribution), (2) empirical Bayes / moderated t-tests (for low sample size; e.g. n < 10; parametric), (3) Mann-Whitney-U [16] , while the qvalue library provides an implementation for the rank-preserving q-value calculation (Code 10).
Nominally differentially expressed probes (e.g. with a single-test level of p < 0.05) can also be filtered by multiple-testing correction, for example by applying a q-value / FDR cutoff (common cut-off, e.g. 0.1) to ensure a low proportion of false-positives in the set of probes to be subsequently followed up. To reduce time in the analysis, it may also be useful to exclude genes / probes that are not expected to be differentially expressed either due to biologically low variability in the investigated samples, or due to technically low detectability on the array. This can be achieved either by non-specific filtering of expression values restricted to a given range (e.g. the shortest interval containing half of the data by standard deviation (sd) or interquartile range) or by setting an empirical cut-off to the coefficient of variation (sd/mean), e.g. the top 10 percent or a fixed value of 0.6. Note, however, that this may increase the rate of false-negative findings (Code 11).
Pitfalls: Batch-correction and Contamination Estimation
When comparing GEP data obtained in the same laboratory, but with two or more different batches of arrays, the results will deviate from one another beyond the expected biological and arrayspecific technical variation. Batch correction addresses this issue. Two approaches commonly considered to be performing best [17] are mean-centering and a Bayesian framework named When comparing the black dot to gray dots (all other samples), one can observe that the sample is among those with highest purity. Lower panel: sample among those with lowest purity.
Making Use of Public Databases
Two public databases are commonly used for the comparison of own microarray data with independent data sets, for example in a meta-analysis, namely the GEO (gene expression omnibus)
database [21] (http://www.ncbi.nlm.nih.gov/geo) and the ArrayExpress database [22] (https://www.ebi.ac.uk/arrayexpress), with GEO featuring a larger number of integrated samples.
Both platforms use distinct annotation / meta-data file systems. In GEO, samples are either described in MIAME Notation in Markup Language (MINiML; pronounced 'minimal') or SOFT formatted family files. In ArrayExpress, sample and data relationships (SDR) are described in the SDRF format, Implemented queries include:
• "Query 1: Get experiments where the sample description contains diabetes"
• "Query 2: Get differentially expressed genes where factor is asthma"
• "Query 3: Show expression for ENSG00000129991 (TNNI3)"
• "Query 4: Show expression for ENSG00000129991 (TNNI3) with its GO annotations from Uniprot (Federated query to http://sparql.uniprot.org/sparql)"
• "Query 5: For the genes differentially expressed in asthma, get the gene products associated to a Reactome pathway"
• "Query 6: Get all mappings for a given probe e. Table 3 ). User's familiarity with the underlying ontologies (controlled vocabulary; [24] ) is, however, necessary to construct queries.
Meta Analyses: Exploring Possible Phenotypic Markers across Different Conditions
For conceptualizing a pharmacologic compound (e.g. inhibitor) acting against a specific gene product or for designing specific gene-knockouts within a model organism, it may be particularly Since not all 'ArrayExpress' data sets are yet integrated into the EMBL / EBI RDF platform and the GEO database contains additional data sets, the manual download, processing, and integration of such additional data is often necessary.
Therefore, a second, more hands-on approach to meta-analyses is a search by keyword, e.g.
'chronic lymphoid', within GEO and / or ArrayExpress (or any other public database). Once the data set has been picked, it is background-corrected and the annotated replicates can be combined with their original samples by calculating their mean. Afterwards all samples within the data set are normalized (e.g. quantile-normalized).
Probe sets of a gene which map to retained / dysfunctional transcripts (or which map to more retained / dysfunctional transcripts than other probe sets of the same gene) should be removed to obtain meaningful expression values (Suppl. 2) Batch effects cannot be entirely excluded by using method 1) as may be observed by a bias in clustering of samples from the same experiment. Therefore, we recommend a novel method called inSilicoMerge [25] , which combines data sets and removes their batch effect with a choice of various methods, such as the empirical Bayes method ComBat (Figure 3c ).
Unfortunately, data sets from different platforms can only be combined gene-wise, meaning that e.g. MCL1 would not be deconvolutable into its isoforms MCL-001 / MCL1-long and MCL-002 / MCL1-short. Default setting is the Student's t-test, except for low variation or non-normal distributions, for which the non-parametric Wilcoxon rank sum test is recommended. Atlas RDF (see Table 3 for exact query). The output, in table format, can be further exported into e.g. csv format. Fold-changes can be further visualized as in c). b) Example taken from [49] (Fig. 1a) : mature T-cell lymphomas and normal T-cell subsets are grouped by expression of pro-and anti-apoptotic BCL2 family genes / isoforms. The long MCL1 isoform seems to be used throughout malignant and benign T-cells, while BCL2A1 and BCL2L11 seem to be especially upregulated in malignant T-cells. Samples were quantile-normalized on the basis of 12 markers. c) Example taken from [50] . with post-to-pretreatment and other clinical comparisons.
Functional Analyses: the More the Merrier
In the abundance of genes obtained as significantly dysregulated, the role or function of a specific gene is often unknown and it is therefore encouraged to group them functionally by software Other user-friendly and open-source alternatives include DAVID [26] , gene set over-representation analysis (GSOA) by ConsensusPathDB [27] (Suppl. Figure 2) , and gene set enrichment analysis (GSEA; Figure 4a ) by the Broad Institute [28] . All three tools can be operated from web GUIs, while the first two options also offer an R implementation or in the case of GSEA, also a JAVA desktop application. 
Standard Survival Analysis and An Exploratory / Heuristic Approach
Besides parameters of more established nature (routinely tested), e.g. in CLL those from clinical chemistry, such as β 2
An univariate analysis compares time-to-event parameters for two subgroups divided by a gene expression or other marker status (see [32] for an introduction). For multivariate analysis, multiple genes or markers are considered for a competing subset comparison (see [33] for an introduction).
For the former there are standard methods implemented within the R library survival with functions survdiff to test the differences of survival times with the log-rank test [34] and survfit to plot the survival times with the Kaplan-Meier estimator [35] (Code 17). A multivariate analysis allows ranking of the most significant markers contributing to an adverse prognosis. It is usually conducted with the Cox Proportional Hazards [36] (CoxPH) model. microglobulin [30] or from immunophenotyping, such as ZAP70 [31] , the expression of a single gene or a gene set detected by microarray-based GEP can also serve as a marker, or a scored combination of them, that predict clinical outcomes. Such prognostic estimations are predominantly measured in subgroup differences of time-to-event metrics like overall survival (OS; from date of diagnosis or less correctly from first day of treatment or study randomization to last follow-up (FU) or death) or progression-free survival (PFS; from first day of treatment or randomization to disease progression or death). Other measurements include time-to-treatment (TTT; from diagnosis or randomization to first day of treatment), time-to-next-treatment (TTNT; end of first to beginning of next treatment), time-to-treatment-failure (TTF; time from diagnosis or randomization to treatment dismissal), or event-free survival (EFS; time from diagnosis or randomization to disease progression, death or treatment dismissal). These parameters are either right-censored (date of death or progression after study window, thus unknown) or left-censored (study entry is unknown) to deal with missing time points or events (death or progression). Here we focus on right-censored data.
As evidence provided by different data sources and methods strengthens a given hypothesis, it is important to validate identified markers of prognosis in an independent patient cohort. However, this is often difficult due to a limited availability of reasonably-sized data sets for comparison.
Possible causes may be a low disease incidence (e.g. notorious for mature T-cell lymphomas) or general difficulties in obtaining primary tumor samples (e.g. due to the need of invasive procedures to be consented by the patient). Another factor imposing limitations on sample size is the uniformity of received treatments, which must apply to a given patient cohort in order to reliably predict related outcomes. For GEP studies in such scenarios, we propose an alternative algorithm for the identification of prognostic gene expression signatures, which we demonstrate by the example of GEP data generated from peripheral blood tumor samples of patients with T-cell prolymphocytic leukemia (T-PLL) and CLL. We obtained gene expression profiles from 49 T-PLL samples with available OS status and from 58 chemoimmunotherapy-treated CLL patients with available PFS data, both from Illumina HumanHT-12 v4.0 Expression BeadChips. In a first training set of 10 T-PLL, 5 patients with longest OS (time from diagnosis to death of disease, > 800 days) were compared to those with shortest OS (< 300 days, n = 5) using the 'Significance analysis of microarrays' (SAM) analysis in survival mode via the R library samr [37] . We only considered expression profiles from patients in whom corresponding samples Suppl. Figure 5) ; measured by ANOVA for numerical or by entropy for categorical values. When looking for a cut-off for adverse prognosis, they can be further used in the form of regression trees [41] . Different parameters can be controlled in this approach, such as the maximum size of a tree or the number of portions / bins. It is recommended to keep these relatively low in the training set to avoid "overfitting" and thus enable re-evaluation in the test set. Random forests [42] (as an assembly of permutated decision trees) can be used to determine the chance of observing random tree branching (library randomForest) (Code 21). Both algorithms are also included in the rattle library, which offers a user-friendly GUI with interactive plots and a selection menu for class variable and co-variates as well as algorithm and parameter choices. For a more detailed review on current machine learning algorithms in GEP, we refer to [43] . amplification, MYC mRNA upregulation, ATM mRNA downregulation, and TCL1A mRNA upregulation. ATM deletion status seems to be the most informative co-variate, however due to the excessive size of the tree (controlled by pruning and number of bins) there is a risk of "overfitting". f) Shown is a more feasible and smaller decision tree. Again, the most informative co-variate seems to be the status of ATM gene deletion. Followed by AGO2 amplification status.
This is further confirmed in random forests (permutated decision trees) in order to circumvent 'overfitting' (not shown).
Discussion
In this review we discuss procedures to optimize GEP analyses. We highlight the importance of methods, originally established for microarray data analysis, can also be applied to RNA-seq data (on the basis of read counts instead of fluorescence values). In addition to GEP, it is always desirable to aim for additional genetic information, including (somatic) copy-number alterations, structural variation, and genotyping of nucleotide variants for a most comprehensive genetic workup of the investigated cancer specimen. Epigenomic data, e.g. from methylome and ChIP-seq experiments may be added as a second layer. Besides setting up an own data repository in MySQL or RDF for managing internal data, one may also investigate the cBioPortal for Cancer Genomics [44] . TCGA (https://tcga-data.nci.nih.gov/tcga), ICGC (https://dcc.icgc.org), and other large curated data sets provide user-friendly search engines with multiple visualization options. Another helpful tool for combining gene expression data with available genomic knowledge in a network-based analysis is
Expander [45] . Overall, this review and the attached source codes may provide guidance to both molecular biologists and bioinformaticians / biostatisticians to properly conduct GEP analyses from microarrays and to go beyond the application of standard analytic tools to optimally interpret the clinical and biological relevance of the obtained results.
